A. Aksnes

678 total citations
20 papers, 551 citations indexed

About

A. Aksnes is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, A. Aksnes has authored 20 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Oncology. Recurrent topics in A. Aksnes's work include Radiopharmaceutical Chemistry and Applications (11 papers), Prostate Cancer Treatment and Research (10 papers) and Bone health and treatments (4 papers). A. Aksnes is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (11 papers), Prostate Cancer Treatment and Research (10 papers) and Bone health and treatments (4 papers). A. Aksnes collaborates with scholars based in Sweden, Norway and United States. A. Aksnes's co-authors include Nils Hjeltnes, Harriet Wallberg‐Henriksson, Sten Nilsson, Øyvind S. Bruland, S. Vasanthan, Lars Franzén, Charlotte Andersson, Patrick Olivier, A Pecking and J. Staffurth and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A. Aksnes

20 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Aksnes Sweden 9 244 233 129 123 99 20 551
Georgios Arsos Greece 17 113 0.5× 81 0.3× 36 0.3× 201 1.6× 30 0.3× 66 772
J. B. Chalk Australia 12 279 1.1× 164 0.7× 37 0.3× 21 0.2× 15 0.2× 15 795
África Muxí Spain 19 133 0.5× 170 0.7× 143 1.1× 202 1.6× 24 0.2× 59 970
Saskia H. Meves Germany 19 242 1.0× 195 0.8× 26 0.2× 13 0.1× 249 2.5× 47 924
Takayuki Matsuki Japan 12 60 0.2× 81 0.3× 57 0.4× 43 0.3× 16 0.2× 33 456
K Forfang Norway 10 155 0.6× 214 0.9× 69 0.5× 49 0.4× 88 0.9× 26 940
Jakob Schöpe Germany 15 228 0.9× 53 0.2× 72 0.6× 87 0.7× 16 0.2× 30 623
H.-M. Chang South Korea 15 497 2.0× 92 0.4× 74 0.6× 135 1.1× 12 0.1× 24 828
C.P. Oates United Kingdom 10 230 0.9× 67 0.3× 15 0.1× 37 0.3× 47 0.5× 15 499
Erol Tülümen Germany 20 94 0.4× 177 0.8× 31 0.2× 26 0.2× 45 0.5× 67 996

Countries citing papers authored by A. Aksnes

Since Specialization
Citations

This map shows the geographic impact of A. Aksnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Aksnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Aksnes more than expected).

Fields of papers citing papers by A. Aksnes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Aksnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Aksnes. The network helps show where A. Aksnes may publish in the future.

Co-authorship network of co-authors of A. Aksnes

This figure shows the co-authorship network connecting the top 25 collaborators of A. Aksnes. A scholar is included among the top collaborators of A. Aksnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Aksnes. A. Aksnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Morris, Michael J., Celestia S. Higano, Howard I. Scher, et al.. (2014). Safety of Radium-223 Dichloride (Ra) with Docetaxel (D) in Patients (Pts) with Bone Metastases (Mets) from Castration-Resistant Prostate Cancer (Crpc): a Phase 1/2A Clinical Trial. Annals of Oncology. 25. iv261–iv261. 7 indexed citations
4.
5.
Michalski, Jeff M., Oliver Sartor, Chris Parker, et al.. (2013). Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial. International Journal of Radiation Oncology*Biology*Physics. 87(2). S108–S109. 3 indexed citations
6.
Nilsson, Sten, Peter Strang, A. Aksnes, et al.. (2012). A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer. 48(5). 678–686. 191 indexed citations
7.
8.
Lewington, Valerie, Chris Parker, Cécilia Hindorf, et al.. (2010). Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.. Journal of Clinical Oncology. 28(15_suppl). e15009–e15009. 2 indexed citations
9.
10.
Carrasquillo, Jorge A., Neeta Pandit‐Taskar, Dana E. Rathkopf, et al.. (2010). Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone.. Journal of Clinical Oncology. 28(15_suppl). 4680–4680. 3 indexed citations
11.
Nilsson, Stefan, et al.. (2009). Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined safety analyses of phase I and II clinical trials. 2 indexed citations
12.
Halpern, Ethan J., et al.. (2002). Contrast-enhanced US of the Prostate with Sonazoid: Comparison with Whole-Mount Prostatectomy Specimens in 12 Patients. Radiology. 222(2). 361–366. 71 indexed citations
13.
Magnusson, Å., et al.. (2001). ENHANCED VISUALISATION OF THE NORMAL PROSTATE BLOOD FLOW IN YOUNG HEALTHY VOLUNTEERS USING A NEW ULTRASOUND CONTRAST AGENT. Acta Radiologica. 42(2). 225–229. 10 indexed citations
14.
Magnusson, Åsa, et al.. (2001). Enhanced visualisation of the normal prostate blood flow in young healthy volunteers using a new ultrasound contrast agent. Acta Radiologica. 42(2). 225–229. 5 indexed citations
15.
Brundin, T., A. Aksnes, & J. Wahren. (1997). Whole body and splanchnic metabolic and circulatory effects of glucose during beta-adrenergic receptor inhibition. American Journal of Physiology-Endocrinology and Metabolism. 272(4). E678–E687. 10 indexed citations
16.
Hjeltnes, Nils, A. Aksnes, K. I. Birkeland, et al.. (1997). Improved body composition after 8 wk of electrically stimulated leg cycling in tetraplegic patients. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 273(3). R1072–R1079. 109 indexed citations
17.
Aksnes, A., et al.. (1996). Intact glucose transport in morphologically altered denervated skeletal muscle from quadriplegic patients. American Journal of Physiology-Endocrinology and Metabolism. 271(3). E593–E600. 69 indexed citations
18.
Aksnes, A., T. Brundin, Nils Hjeltnes, & J. Wahren. (1995). Metabolic, thermal and circulatory effects of intravenous infusion of amino acids in tetraplegic patients. Clinical Physiology. 15(4). 377–396. 16 indexed citations
19.
Aksnes, A., T. Brundin, Nils Hjeltnes, & J. Wahren. (1994). Glucose-induced thermogenesis in tetraplegic patients with low sympathoadrenal activity. American Journal of Physiology-Endocrinology and Metabolism. 266(2). E161–E170. 16 indexed citations
20.
Aksnes, A., et al.. (1993). Pulmonary function and symptom-limited exercise stress testing in subjects with late sequelae of poliomyelitis. Journal of Rehabilitation Medicine. 25(3). 125–129. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georgios Arsos Breakdown of academic impact, for papers by J. B. Chalk Breakdown of academic impact, for papers by África Muxí Breakdown of academic impact, for papers by Saskia H. Meves Breakdown of academic impact, for papers by Takayuki Matsuki Breakdown of academic impact, for papers by K Forfang Breakdown of academic impact, for papers by Jakob Schöpe Breakdown of academic impact, for papers by H.-M. Chang Breakdown of academic impact, for papers by C.P. Oates Breakdown of academic impact, for papers by Erol Tülümen
Rankless by CCL
2026